Related Experiment Video
Updated: Jun 29, 2025
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma
John Devin Peipert1, Fengmin Zhao2, Ju-Whei Lee2
1Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
JAMA Network Open
|March 27, 2024
Summary
Patient-reported outcomes (PROs) effectively predict early treatment discontinuation (ETD) in multiple myeloma. A simple PRO question about adverse event bother can efficiently identify patients at risk for ETD.
Area of Science:
- Oncology
- Clinical Trials
- Patient-Reported Outcomes
Background:
- Capturing patient perspectives on cancer treatment tolerability is crucial.
- Patient-reported outcomes (PROs) offer a valuable tool for this assessment.
Purpose of the Study:
- To evaluate if a specific PRO question (GP5) predicts early treatment discontinuation (ETD) due to adverse events in multiple myeloma patients.
- To determine the association between patient-reported bother from adverse events and ETD.
Main Methods:
- A prospective survey study analyzed data from the ECOG-ACRIN E1A11 trial involving newly diagnosed multiple myeloma patients.
- The Functional Assessment of Cancer Therapy-General Physical Wellbeing Scale (GP5) item was administered at multiple time points.
- Logistic regression was used to analyze the association between GP5 responses and ETD, adjusting for covariates.
Main Results:
- A higher level of bother reported on the GP5 item was significantly associated with increased odds of ETD at 1, 2.8, and 5.5 months.
- Worsening GP5 responses by two or more categories also correlated with a higher risk of ETD at later time points.
- Approximately 13.4% of patients discontinued treatment early due to adverse events.
Conclusions:
- Worse patient-reported bother on the GP5 item is a significant predictor of early treatment discontinuation in multiple myeloma.
- This simple PRO assessment serves as an efficient method to gauge treatment tolerability and identify patients at risk for ETD.
